IL36RN
Interleukin-36 receptor antagonist protein
Also known as: FIL1, FIL1(DELTA), FIL1D, I36RA_HUMAN, IL-1F5, IL1F5, IL1HY1, IL1L1, IL1RP3, IL36RA, MGC29840
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UBH0
- Gene
- IL36RN
- Ensembl
- ENSG00000136695
- Chromosome
- 2
- Canonical length
- 155 aa
- Protein class
- Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted secreted proteins
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene is a member of the interleukin 1 cytokine family. This cytokine was shown to specifically inhibit the activation of NF-kappaB induced by interleukin 1 family, member 6 (IL1F6). This gene and eight other interleukin 1 family genes form a cytokine gene cluster on chromosome 2. Two alternatively spliced transcript variants encoding the same protein have been reported. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
155 residues, UniProt reviewed canonical sequence.
>Q9UBH0|IL36RN
1 MVLSGALCFR MKDSALKVLY LHNNQLLAGG LHAGKVIKGE EISVVPNRWL DASLSPVILG
61 VQGGSQCLSC GVGQEPTLTL EPVNIMELYL GAKESKSFTF YRRDMGLTSS FESAAYPGWF
121 LCTVPEADQP VRLTQLPENG GWNAPITDFY FQQCDLocalizationUniProt · AlphaFold · HPA
Whether an antibody against IL36RN can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.3
- Highest tissue expression
- 60 nTPM
Expression across tissuesHPA
Tissue
- skin: 60 nTPM
- tonsil: 42 nTPM
- esophagus: 26 nTPM
- cervix: 13 nTPM
- vagina: 8.5 nTPM
- salivary gland: 4 nTPM
Single-cell type
- esophageal apical cells: 327 nCPM
- ocular epithelial cells: 25 nCPM
- migrating cytotrophoblasts: 15 nCPM
- esophageal suprabasal cells: 12 nCPM
- suprabasal keratinocytes: 10 nCPM
- cytotrophoblasts: 9.1 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- basal ganglia: 0.1 nTPM
- cerebral cortex: 0.1 nTPM
- medulla oblongata: 0.1 nTPM
- thalamus: 0.1 nTPM
- white matter: 0.1 nTPM
- amygdala: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about IL36RN.
Disease | AllUniProt
Conditions IL36RN is implicated in, by any mechanism.
- Psoriasis 14, pustular (PSORS14) MIM:614204
Disease | GeneticClinVar
13 pathogenic / likely-pathogenic of 213 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Generalized pustular psoriasis
- Acrodermatitis continua suppurativa of Hallopeau
- Autoinflammatory syndrome
- IL36RN-related disorder
ReferencesPubMed · IEDB
Publications for IL36RN from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Autoantibody-Mediated Depletion of IL-1RA in Still's Disease and Potential Impact of IL-1 Targeting Therapies.
2024 · J Clin Immunol · RCR 2 · 11 citations - Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis.
2024 · Immunol Lett · RCR 1.2 · 6 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.9
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.43
- DepMap mean gene effect
- -0.02
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- antifungal humoral response
- cellular response to lipopolysaccharide
- immune response
- inflammatory response
- innate immune response
- negative regulation of cytokine-mediated signaling pathway
- negative regulation of interleukin-17 production
- negative regulation of interleukin-6 production
- negative regulation of type II interferon production
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of IL36RN in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads IL36RN as an antibody target. Whether an autoantibody or antibody against IL36RN could matter depends on whether native IL36RN is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
IL36RN is annotated as secreted, so native IL36RN circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label IL36RN as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...